Worldwide prostate cancer trial now open internationally A new cancer trial for men with high risk, clinically localised prostate cancer has now opened in Australia, New Zealand, Canada, USA, Ireland and the UK. The DASL- HiCaP trial (ANZUP1801), led by ANZUP Cancer Trials Group, enrolled its first patient at the Chris O’Brien Lifehouse in Camperdown, Sydney in April 2020. Prostate cancer remains the most common cancer in Australian men and the leading cause of cancer related-mortality for men in developed countries. This new randomised phase 3 study aims to demonstrate that the addition of a new potent oral hormonal therapy, darolutamide,
“It was great to see DASLHiCaP open for recruitment in Canada, after many months of negotiations and setbacks due to COVID-19. I look forward to the trial opening in more sites across Canada in the coming months.”
to standard radiation therapy and testosterone suppression, improves the outcomes of men with localised high-risk prostate cancer. Outcomes of the trial will be measured in terms of whether the addition of darolutamide decreases the risk of spread of prostate cancer to other parts of the body as well as improving quality of life and potentially decrease the risk of prostate cancer death. This trial aims to recruit and follow up 1,100 eligible patients across over 100 cancer centres internationally – so it is exciting to see the trial opening at all centres with patient recruitment also beginning.
“Our hope is that this trial will define a new treatment paradigm by decreasing the risk of a relapse after local therapy for high risk localised prostate cancer.” Study Co-Chair Professor Christopher Sweeney
A/Professor Tamim Niazi DASL-HiCaP Co-Chair
A LITTLE BELOW THE BELT 25
